Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study
Jarred Younger PhD
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, Palo Alto, California, USA
Search for more papers by this authorSean Mackey MD, PhD
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, Palo Alto, California, USA
Search for more papers by this authorJarred Younger PhD
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, Palo Alto, California, USA
Search for more papers by this authorSean Mackey MD, PhD
School of Medicine, Department of Anesthesia, Division of Pain Management, Stanford University, Palo Alto, California, USA
Search for more papers by this authorABSTRACT
Objective. Fibromyalgia is a chronic pain disorder that is characterized by diffuse musculoskeletal pain and sensitivity to mechanical stimulation. In this pilot clinical trial, we tested the effectiveness of low-dose naltrexone in treating the symptoms of fibromyalgia.
Design. Participants completed a single-blind, crossover trial with the following time line: baseline (2 weeks), placebo (2 weeks), drug (8 weeks), and washout (2 weeks).
Patients. Ten women meeting criteria for fibromyalgia and not taking an opioid medication.
Interventions. Naltrexone, in addition to antagonizing opioid receptors on neurons, also inhibits microglia activity in the central nervous system. At low doses (4.5 mg), naltrexone may inhibit the activity of microglia and reverse central and peripheral inflammation.
Outcome Measures. Participants completed reports of symptom severity everyday, using a handheld computer. In addition, participants visited the lab every 2 weeks for tests of mechanical, heat, and cold pain sensitivity.
Results. Low-dose naltrexone reduced fibromyalgia symptoms in the entire cohort, with a greater than 30% reduction of symptoms over placebo. In addition, laboratory visits showed that mechanical and heat pain thresholds were improved by the drug. Side effects (including insomnia and vivid dreams) were rare, and described as minor and transient. Baseline erythrocyte sedimentation rate predicted over 80% of the variance in drug response. Individuals with higher sedimentation rates (indicating general inflammatory processes) had the greatest reduction of symptoms in response to low-dose naltrexone.
Conclusions. We conclude that low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for fibromyalgia.
References
- 1 Nuemann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003; 7: 362–8.
- 2 White KP, Speechley M, Harth M, et al. The London fibromyalgia study: The prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999; 26: 1570–6.
- 3 Yunus MB. Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation. J Rheumatol 1992; 19: 846–50.
- 4 Waylonis GW, Heck W. Fibromyalgia syndrome. New associations. Am J Phys Med Rehabil 1992; 71: 343–8.
- 5 Kaplan KH, Goldenberg DL, Galvin-Nadeau M. The impact of a meditation-based stress reduction program on fibromyalgia. Gen Hosp Psychiatry 1993; 15: 284–9.
- 6 Boissevain MD, McCain GA. Toward an integrated understanding of fibromyalgia syndrome. I. Medical and pathophysiological aspects. Pain 1991; 45: 227–38.
- 7 Kashikar-Zuck S, Graham TB, Huenefeld MD, Powers SW. A review of biobehavioral research in juvenile primary fibromyalgia syndrome. Arthritis Care Res 2000; 13: 388–97.
- 8 Perrot S. Fibromyalgia syndrome: A relevant recent construction of an ancient condition? Curr Opin Support Palliat Care 2008; 2: 122–7.
- 9 Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008; 14: 1274–94.
- 10 Cook DB, Stegner AJ, McLoughlin MJ. Imaging pain of fibromyalgia. Curr Pain Headache Rep 2007; 11: 190–200.
- 11 Price DD, Staud R, Robinson ME, et al. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002; 99: 49–59.
- 12 Mease P. Fibromyalgia syndrome: Review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005; 75: 6–21.
- 13 Staud R. New insights into the pathogenesis of fibromyalgia syndrome: Important role of peripheral and central pain mechanisms. Curr Rheumatol Rev 2007; 3: 113–21.
- 14 Yunus MB. Fibromyalgia and overlapping disorders: The unifying concept of central sensitivity syndromes. Semin Arthritis Rheum 2007; 36: 339–56.
- 15 Thompson ME, Barkhuizen A. Fibromyalgia, hepatitis C infection, and the cytokine connection. Curr Pain Headache Rep 2003; 7: 342–7.
- 16 Wallace DJ. Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006; 12: 17–22.
- 17 Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25: 225–30.
- 18 Crofford LJ, Rowbotham MC, Mease PJ, et al. Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. American College of Rheumatology 2005; 52: 1264–73.
- 19 Arnold LM, Lu Y, Crofford LJ, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974–84.
- 20 Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975–85.
- 21
Krypel LL.
Fibromyalgia: A review of its pathophysiology and drug treatment.
J Pharm Pract
2009; 22: 6–16.
10.1177/0897190008322151 Google Scholar
- 22 Lawson K. Pharmacological treatments of fibromyalgia: Do complex conditions need complex therapies? Drug Discov Today 2008; 13: 333–40.
- 23 Liu B, Hong JS. Neuroprotective effect of naloxone in inflammation-mediated dopaminergic neurodegeneration: Dissociation from the involvement of opioid receptors. Methods Mol Med 2002; 79: 43–54.
- 24 Liu B, Du L, Kong L-Y, et al. Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron-glia co-cultures. Neuroscience 2000; 97: 749–56.
- 25 Czlonkowski A, Stein C, Harz A. Peripheral mechanisms of opioid antinociception in inflammation: Involvement of cytokines. Eur J Pharmacol 1993; 242: 229–35.
- 26 Greeneltch KM, Haudenschild CC, Keegan AD, et al. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immun 2004; 18: 476–84.
- 27 Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000; 293: 607–17.
- 28 Tsai RY, Jang FL, Tai YH, et al. Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats. Neuropsychopharmacology 2008; 33: 2772–82.
- 29 Liu B, Jiang JW, Wilson BC, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000; 295: 125–32.
- 30 Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience 2008; 28: 20–9.
- 31 San-Emeterio EP, Hurlé MA. Modulation of brain apoptosis-related proteins by the opioid antagonist naltrexone in mice. Neurosci Lett 2006; 403: 276–9.
- 32 Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. Cancer Invest 1995; 13: 561–6.
- 33 Smith JP, Stock H, Bigaman S, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J of Gastroenterol 2007; 102: 820–8.
- 34 Gironi M, Martinelli-Boneschi F, Sacerdote P, et al. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 2008; 14: 1076–83.
- 35 Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160–72.
- 36 De Boer AGEM, Van Lanschot JJB, Stalmeier PFM, et al. Is a single-item visual analogue scale as valid, reliable, and responsive as multi-item scales in measuring quality of life? Qual Life Res 2004; 13: 311–20.
- 37 Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: Development and validation. J Rheumatol 1991; 18: 728–33.
- 38 Bejamini Y, Yekutieli D. The control of false discovery rate under dependency. Ann Stat 2001; 29: 1165–88.
- 39 Narum SR. Beyond Bonferroni: Less conservative analyses for conservation genetics. Conserv Genet 2006; 7: 783–7.
- 40 Farrar JT, Young JP, LaMoreaux L, et al. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 149–58.
- 41 Faul F, Erdfelder E, G Lang A-G, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175–91.
- 42 Viitanen JV, Kautiainen H, Isomäki H. Pain intensity in patients with fibromyalgia and rheumatoid arthritis. Scand J Rheumatol 1993; 22: 131–5.
- 43 Leeb BF, Andel I, Sautner J, et al. The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology 2004; 43: 1504–7.
- 44 Pamuk Ö, Çakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol 2007; 26: 55–9.
- 45 Giesecke T, Williams DA, Harris RE. Subgrouping of fibromyalgia patients on the basis in pressure-pain thresholds and psychological factors. Arthritis Rheum 2003; 48: 2916–22.
- 46 Robinson RL, Birnbaum HG, Morley MA, et al. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheum 2003; 30: 1318–25.
- 47 Penrod J, Adam V, Bernatsky S, et al. Direct and indirect costs of fibromyalgia in women. J Rheum 2004; 31: 1391–8.
- 48 Mitchell JE. Naltrexone and hepatotoxicity. Lancet 1986; 1: 1215.
- 49 Debruyne JC, Versijpt J, Van Laere KJ, et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003; 10: 257–64.
- 50 Venneti S, Wagner AK, Wang G, et al. The high affinity peripheral benzodiazepine receptor ligand DAA1106 binds specifically to microglia in a rat model of traumatic brain injury: Implications for PET imaging. Exp Neurol 2007; 207: 118–27.
